Financial Data and Key Metrics Changes - The company ended Q1 2024 with $1.7 billion in cash and investments, down from $1.85 billion at the end of 2023, primarily due to net loss and a decrease in accounts payable and accrued liabilities [15][34] - R&D expenses for Q1 2024 were $118.0 million, compared to $68.9 million in Q1 2023, driven by clinical trial expenses [34] - The net loss for Q1 2024 was $116.0 million, or $0.70 per share, with a projected full-year GAAP net loss expected to be between $480 million and $520 million [35] Business Line Data and Key Metrics Changes - The company is focused on advancing RMC-6236 into pivotal monotherapy trials for major cancers driven by oncogenic RAS variants, with updates expected in the second half of the year [23][24] - RMC-6236 is being evaluated in combination studies for pancreatic and colorectal cancers, which are crucial for establishing first-line registrational paths [9][10] Market Data and Key Metrics Changes - The company anticipates that the first registrational studies for RMC-6236 will launch in the second half of the year, targeting advanced pancreatic cancer and non-small cell lung cancer [14][24] - The competitive landscape includes other KRAS G12C inhibitors, but the company believes that RMC-6236 will provide a treatment option for patients without G12C mutations [42][44] Company Strategy and Development Direction - The company has outlined three strategic priorities for 2024: advancing RMC-6236 into pivotal trials, expanding its reach beyond G12X mutations, and qualifying its first two RAS(ON) mutant-selective inhibitors [4][25][28] - The company is exploring combination therapies to enhance treatment efficacy and is committed to moving RMC-6236 into earlier lines of therapy [27][29] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of RMC-6236, citing complete responses in some patients and the importance of targeting RAS addiction [26][32] - The company is well-capitalized and focused on delivering key data to advance its clinical programs, with a strong emphasis on safety and efficacy in combination therapies [36][37] Other Important Information - The company presented data at the AACR Annual Meeting, highlighting the potential of RMC-6236 across various RAS genotypes and tumor types [25][80] - Management emphasized the importance of establishing safety profiles for combination therapies before moving forward with clinical development [106][107] Q&A Session Summary Question: What questions are still being addressed for the pancreatic cancer study design? - The company needs to reach an agreement with the FDA on dosing and trial design, which are expected to be resolved in the first half of the year [37] Question: Will the first-line study wait for second-line trial results? - The company is evaluating both monotherapy and combination options for first-line treatment but has not made a definitive decision yet [39] Question: How might the KRYSTAL 12 trial results impact the company's studies? - The company believes that the impact will be minimal for pancreatic cancer, as G12C represents a small subpopulation [42] Question: What is the expected timeline for initial data from the RMC-6236 and pembrolizumab combination? - Initial safety data will likely not be from first-line patients, but the study is designed to enable a first-line strategy [46][51] Question: What is the company's approach to business development? - The company is committed to U.S. operations and plans to commercialize its compounds independently, while seeking partners for international markets [117][124]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number: 001-39219 Revolution Medicines, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 47-2029180 | | --- | ...

Exhibit 99.1 Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., May 8, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2024, and provided an update on corporate progress. The comp ...

Financial Data and Key Metrics Changes - The company ended 2023 with $1.85 billion in cash and investments, expected to fund operations into 2027 [18] - Collaboration revenue for Q4 2023 was $0.7 million, down from $15.3 million in the prior year quarter, and full-year revenue was $11.6 million compared to $35.4 million in the previous year [19] - Total operating expenses for Q4 2023 increased to $180.7 million, driven by R&D expenses totaling $148.5 million, while full-year operating expenses reached $498.8 million [26] - The net loss for Q4 2023 was $161.5 million, or $1.14 per share, and for the full year, the net loss was $436.4 million, or $3.86 per share [27][28] Business Line Data and Key Metrics Changes - The company reported favorable trends in aggregate objective response rates (ORR) for RMC-6236 in non-small cell lung cancer, reaching the low to mid-40s range, and in pancreatic ductal adenocarcinoma, trending into the mid-20s [12][13] - RMC-9805, an oral G12D selective inhibitor, has confirmed oral bioavailability in patients, with no dose-limiting toxicities reported [16][17] Market Data and Key Metrics Changes - The company is expanding the reach of RMC-6236 to include patients with tumors harboring RAS mutations beyond G12X, including G13X and Q61X mutations, and studying it in various tumor types beyond lung and pancreatic cancer [14] Company Strategy and Development Direction - The company has three strategic priorities for 2024: advancing RMC-6236 into pivotal trials, expanding its reach, and qualifying RMC-6291 and RMC-9805 for late-stage development [11][15] - The company aims to propel RMC-6236 into its first pivotal trial against standard-of-care chemotherapy for RAS-mutated non-small cell lung cancer and pancreatic ductal adenocarcinoma [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong balance sheet and pipeline, emphasizing the commitment to developing targeted therapies for patients with RAS-addicted cancers [24][29] - The company anticipates disclosing initial clinical data for RMC-6236 and its combinations in the second half of 2024, with a focus on safety and efficacy [15][40] Other Important Information - The company reported that the increase in expected GAAP net loss for 2024 is due to increased expenses associated with ongoing clinical development programs [28] - Management highlighted the importance of establishing a safety profile for combinations with checkpoint inhibitors before moving into first-line treatment settings [33] Q&A Session Summary Question: What data is needed to move combinations with pembrolizumab into pivotal development? - Management is primarily looking to validate safety, particularly concerning hepatotoxicity signals [33] Question: How much more data is needed to support initiation of Phase 3 trials for RMC-6236? - A mature progression-free survival (PFS) assessment is required, along with FDA input [39] Question: What are the gating steps for starting a frontline pancreatic combination study? - The company is exploring combinations with standard regimens like modified FOLFIRINOX and gem-ABRAXANE, focusing on response rates and survival benefits [54] Question: What is the primary endpoint for the Phase 3 trial in second-line pancreatic cancer? - The current thinking is to evaluate both PFS and overall survival (OS) as endpoints [64] Question: What indications should be expected for data updates from expansion cohorts? - Data will be provided for various RAS genotypes and tumor types, including colorectal cancer, in the second half of the year [72] Question: How does the company view partnering opportunities? - The company aims to build its own franchise in the U.S. but is open to partnerships outside the U.S. for commercialization [100][102]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Washington, D.C. 20549 For the fiscal year ended December 31, 2023 OR FORM 10-K (Mark One) Revolution Medicines, Inc. (Exact name of Registrant as specified in its Charter) | Delaware | 47-2029180 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | | 700 Saginaw Drive | | | Redwood City, CA | 94063 ...

November 6, 2023 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, availability of funding, ability to manage existing collaborations and establish new strategic collaborations, licensing or other arrangements, the scope, ...

Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Erin Graves - Senior Director of Corporate Communications and IR Mark Goldsmith - Chairman and CEO Jack Anders - CFO Steve Kelsey - President of Research & Development Conference Call Participants Marc Frahm - TD Cowen Eric Joseph - JPMorgan Jonathan Chang - Leerink Partners Ami Fadia - Needham Alec Stranahan - Bank of America Operator Good day, and thank you for standing by. Welcome to ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number: 001-39219 Revolution Medicines, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-2029180 (State or ...

Financial Data and Key Metrics Changes - The company ended Q2 2023 with $909.5 million in cash, cash equivalents, and investments [8] - Total revenue for Q2 2023 was $3.8 million, primarily from a terminated collaboration agreement with Sanofi [8] - Total operating expenses for Q2 2023 were $112.6 million, driven by clinical trial and manufacturing expenses for RMC-6236 and RMC-6291 [17] - The net loss for Q2 2023 was $98.3 million, or $0.92 per share, with a full-year GAAP net loss guidance of $360 million to $400 million [18][19] Business Line Data and Key Metrics Changes - The company is focusing on the development of RAS(ON) inhibitors, specifically RMC-6236 and RMC-6291, with significant updates expected in the fall [21][72] - The acquisition of EQRx aims to strengthen the company's cash position and support the development of its RAS(ON) inhibitor pipeline [4][5] Market Data and Key Metrics Changes - The company is preparing for clinical updates on RMC-6236 and RMC-6291, with presentations scheduled for the ESMO Congress and the Triple Meeting in October [71][72] - The company is evaluating the potential of RMC-5552 as a RAS Companion Inhibitor in combination with RAS(ON) inhibitors [3][72] Company Strategy and Development Direction - The company is committed to a parallel development approach for its RAS(ON) inhibitor pipeline, aiming to maximize patient benefits quickly [57] - The acquisition of EQRx is intended to provide the financial depth necessary for pursuing multiple late-stage development paths [57] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming clinical updates and the potential for significant advancements in the second half of the year [6][21] - The company is focused on providing hope to patients with RAS-addicted cancers through its innovative drug development efforts [22] Other Important Information - The company plans to initiate pivotal clinical trials for RMC-6236 potentially in 2024, based on encouraging data trends [71][72] - The company is also advancing its oral mutant selective KRAS G12D inhibitor, RMC-9805, with site activation underway [73] Q&A Session Summary Question: Financial guidance and R&D expenses trajectory - The CFO indicated that the second half of the year will see a step-up in R&D expenses compared to the first half, with no guidance provided for 2024 yet [26][27] Question: Single agent path forward for RMC-6236 - Management stated that clinical updates will be provided in the fall, with more visibility expected based on actual data [29] Question: Dose selection for RMC-6236 - The selection of the optimal dose is ongoing, with management committed to ensuring efficacy and tolerability [33][39] Question: Current standard of care for lung and pancreatic cancer - Management discussed the complexities of current treatment options and the need for RMC-6236 to outperform existing therapies [48][50] Question: Pivotal studies for RMC-6236 - Management confirmed a commitment to a parallel approach for late-stage development, depending on data outcomes [57] Question: Update on RMC-5552 - The focus remains on dose optimization for RMC-5552 as a potential RAS Companion Inhibitor, with no immediate plans for single-agent development [60] Question: Plans for assessing different dosing schedules - Management clarified that daily dosing is currently effective, with no immediate plans to explore alternative schedules [62]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number: 001-39219 Revolution Medicines, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-2029180 (State or othe ...